Sign up online today & collaborate
or click here to find out more
Study data published Thursday in the journal Cell clarify the genetic backgrounds of men with metastatic, castration-resistant prostate cancer, revealing that the majority of cases are sensitive to drugs already available or under development. Study author Johann de Bono commented "this is a game changer," adding "it's really going to alter the way we deal with this lethal disease."
Study researchers sequenced tumours from 150 patients with metastatic, castration-resistant prostate cancer that had spread to the bones, soft tissues, lymph nodes and livers. Results showed that 89 percent of men with the disease carried "clinically actionable" mutations, including 62.7 percent with aberrations in the androgen receptor and 65 percent in other cancer-related genes.For more click here
Source: First word pharma